JP6899832B2 - 左心耳を排除するためのデバイスおよび方法 - Google Patents
左心耳を排除するためのデバイスおよび方法 Download PDFInfo
- Publication number
- JP6899832B2 JP6899832B2 JP2018538538A JP2018538538A JP6899832B2 JP 6899832 B2 JP6899832 B2 JP 6899832B2 JP 2018538538 A JP2018538538 A JP 2018538538A JP 2018538538 A JP2018538538 A JP 2018538538A JP 6899832 B2 JP6899832 B2 JP 6899832B2
- Authority
- JP
- Japan
- Prior art keywords
- anchor
- atrial appendage
- left atrial
- laa
- foam
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000005248 left atrial appendage Anatomy 0.000 title claims description 249
- 238000000034 method Methods 0.000 title description 25
- 239000006260 foam Substances 0.000 claims description 137
- 210000005246 left atrium Anatomy 0.000 claims description 39
- 239000000463 material Substances 0.000 claims description 37
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 25
- -1 polytetrafluoroethylene Polymers 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000003146 anticoagulant agent Substances 0.000 claims description 11
- 238000002513 implantation Methods 0.000 claims description 8
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 6
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 6
- 230000002785 anti-thrombosis Effects 0.000 claims description 5
- 230000000149 penetrating effect Effects 0.000 claims description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
- 239000005977 Ethylene Substances 0.000 claims 2
- 210000001008 atrial appendage Anatomy 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 claims 1
- 238000010276 construction Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 description 76
- 239000007943 implant Substances 0.000 description 29
- 239000000853 adhesive Substances 0.000 description 19
- 230000001070 adhesive effect Effects 0.000 description 19
- 230000009545 invasion Effects 0.000 description 18
- 239000011248 coating agent Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 14
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 239000011148 porous material Substances 0.000 description 12
- 230000008467 tissue growth Effects 0.000 description 12
- 239000000306 component Substances 0.000 description 11
- 229910001000 nickel titanium Inorganic materials 0.000 description 11
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 11
- 208000007536 Thrombosis Diseases 0.000 description 9
- 230000005855 radiation Effects 0.000 description 9
- 206010003658 Atrial Fibrillation Diseases 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 8
- 108010035532 Collagen Proteins 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 229920001436 collagen Polymers 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 229920000728 polyester Polymers 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- 229920000954 Polyglycolide Polymers 0.000 description 6
- 230000001746 atrial effect Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000006261 foam material Substances 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 229920001610 polycaprolactone Polymers 0.000 description 6
- 229920000098 polyolefin Polymers 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 5
- 229940127219 anticoagulant drug Drugs 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000004632 polycaprolactone Substances 0.000 description 5
- 239000004633 polyglycolic acid Substances 0.000 description 5
- 210000002620 vena cava superior Anatomy 0.000 description 5
- 235000014676 Phragmites communis Nutrition 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 4
- 239000012867 bioactive agent Substances 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002592 echocardiography Methods 0.000 description 4
- 238000002594 fluoroscopy Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 4
- 239000004626 polylactic acid Substances 0.000 description 4
- 230000003014 reinforcing effect Effects 0.000 description 4
- 210000005245 right atrium Anatomy 0.000 description 4
- 238000013175 transesophageal echocardiography Methods 0.000 description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- 239000010937 tungsten Substances 0.000 description 4
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 3
- 239000004812 Fluorinated ethylene propylene Substances 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 229910045601 alloy Inorganic materials 0.000 description 3
- 239000000956 alloy Substances 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000005770 birds nest Nutrition 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 239000010952 cobalt-chrome Substances 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 210000004491 foramen ovale Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920009441 perflouroethylene propylene Polymers 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- 235000005765 wild carrot Nutrition 0.000 description 3
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000034827 Neointima Diseases 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 2
- 238000004026 adhesive bonding Methods 0.000 description 2
- 229940127218 antiplatelet drug Drugs 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 210000003191 femoral vein Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 2
- 238000003698 laser cutting Methods 0.000 description 2
- 210000005240 left ventricle Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920003226 polyurethane urea Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000012781 shape memory material Substances 0.000 description 2
- 229920001187 thermosetting polymer Polymers 0.000 description 2
- 239000002407 tissue scaffold Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- 229910000619 316 stainless steel Inorganic materials 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 208000006017 Cardiac Tamponade Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- 229940122564 Factor X inhibitor Drugs 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000089486 Phragmites australis subsp australis Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010040201 Polymyxins Proteins 0.000 description 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 description 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 description 1
- 229910000589 SAE 304 stainless steel Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 210000001765 aortic valve Anatomy 0.000 description 1
- 229960003886 apixaban Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000003157 atrial septum Anatomy 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000739 chaotic effect Effects 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 210000003717 douglas' pouch Anatomy 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 239000002565 heparin fraction Substances 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- WABPQHHGFIMREM-UHFFFAOYSA-N lead(0) Chemical compound [Pb] WABPQHHGFIMREM-UHFFFAOYSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000003055 low molecular weight heparin Substances 0.000 description 1
- 229940127215 low-molecular weight heparin Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000002089 prostaglandin antagonist Substances 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940125670 thienopyridine Drugs 0.000 description 1
- 239000002175 thienopyridine Substances 0.000 description 1
- 239000003868 thrombin inhibitor Substances 0.000 description 1
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12177—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure comprising additional materials, e.g. thrombogenic, having filaments, having fibers or being coated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
- A61B17/12122—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder within the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
- A61B17/12168—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure
- A61B17/12172—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device having a mesh structure having a pre-set deployed three-dimensional shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
- A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
- A61B2017/1205—Introduction devices
- A61B2017/12054—Details concerning the detachment of the occluding device from the introduction device
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Surgical Instruments (AREA)
Description
本出願は、その開示全体がすべての目的のために参照により本明細書に組み込まれ、本明細書の一部を形成する、2015年10月12日に出願した米国仮出願第62/240,124号、名称「DEVICES AND METHODS FOR EXCLUDING THE LEFT ATRIAL APPENDAGE」の利益を主張するものである。
5 送達カテーテル
10 デバイス
15 連続気泡発泡体の本体部
17 スロット
20 スキン
25 中心内腔
30 フィニアル
100 心臓
101 内部係止システム
102 左心耳(LAA)
104 左心房(LA)
106 左心室
110 入口部
111 中心ハブ、中心チューブ
120 組織アンカー
121 組織係合セグメント
122 支持セグメント
125 近位領域
130 遠位領域
135 ヒンジ領域
140 係止解除システム
145 リング
147 プルロッド
200 LAA
201 左心房(LA)
202 LA
204 閉塞デバイスまたはプラグ、インプラント
206 層、近位キャップ
208 発泡体プラグ
210 放射線不透過性糸
212 中心内腔
214 通路
216 遠位クリンプ
300 発泡体プラグ
302 糸
304 クリンプ
400 プラグ
401 可撓性アンカー
404 ワイヤ
406 LAA
408 スクリューワイヤ
410 中心内腔
500 チューブ
502 スクリュー
504 LAA壁
506 心外膜面
600 発泡体プラグ
602 左心房面
604 ePTFE材料
606 チューブ状クリンプ
608 内側チューブ
610 LAA面
612 内側層
614 外側層
616 第1の端部
618 第2の端部
700 取付点
800 リム
802 ガイドカテーテル
804 LAA入口部
900 ガイドカテーテル
901 V字型先端部
902 ガイドワイヤ
904 LAA
1000 アンカー
1002 ガイドワイヤ
1003 中心内腔
1006 バルーン
1100 ガイドカテーテル
1101 波V字型先端部
1102 放射線不透過性マーカー
1103 二波V字型先端部
1104 LAA
1108 ガイドワイヤ
1200 ガイドカテーテル
1201 LAA
1202 プッシャー
1203 近位部分
1204 発泡体プラグ
1210 ガイドワイヤ
1300 ガイドカテーテル
1301 プルワイヤ
1302 展開可能なアンカー
1304 中空制約要素、チューブ
1306 ヒンジ
1308 スロット
1400 ガイドカテーテル
1401 ロックワイヤ
1402 ガイド
1404 発泡体プラグ
1405 展開可能なアンカー
1408 遠位バルーン
1412 シャフト
1500 ガイド
1502 シース、シースカバー
1504 係止ループ
1506 展開可能なアンカー
1508 ガイドワイヤバルーン
1514 接着剤
1600 発泡体
1601 外部展開可能アンカー
1602 金属ステント
1603 送達シース
1603 アンカー
1604 外部展開可能アンカー
1604' 近位面
1606 孔
1608 近位頂点
1610 遠位頂点
1612 ジグザグストラット
1700 発泡体プラグ
1702 ワイヤ
1703 ワイヤ
1704 空洞
1705 マウント
1706 近位端
1707 投げ縄
1708 テーパー付きコーン
1709 アンカー
1711 1701ロッド
1800 バネ様インプラントワイヤ
1801 アンカー
1802 発泡体
1803 マウント
1804 ロッド
1807 キャップ
1902 遠位クリンプ要素
2000 プラグ
2002 中心チューブ
2004 被覆
2100 プラグ
2102 ガイドカテーテル
2104 チューブ
2106 プラグ
2202 発泡体材料、発泡体プラグ
2204 ガイドカテーテル
2206 プランジャ
2210 円板形状
2220 シリンダー
2302 バーブ
2304 プラグ
2400 取り出し縫合糸
2402 近位キャップ
2404 ガイドカテーテル
2500 発泡体プラグ
2502 遠位スクリューリード
2504 カテーテルシステム
2506 カテーテルシステム、ガイド
2508 バードネスト
2510 カテーテルシステム、プッシャー
2600 発泡体プラグ
2602 アンカー
2604 バーブ付きリード
Claims (15)
- 近位端と遠位端とを有する連続気泡型の発泡体の本体部(15)であって、前記近位端は抗血栓性を有する血液接触面を備える閉塞領域を含み、前記近位端は左心房に面するように構成され、前記遠位端は左心耳内の植え込みの後に前記左心耳に面するように構成され、該本体部(15)は、送達カテーテル(1、5、1603)内に送達のために圧縮され得るものとされ、前記送達カテーテル(1、5、1603)から取り出されるときに自己拡張することができる、本体部(15)を、含んでなる左心耳閉塞デバイス(10、204)において、
当該左心耳閉塞デバイス(10、204)は、前記本体部(15)内にある中心のハブ(111)と、少なくとも1つの展開可能な組織アンカー(1302、1405、1506、1601、1604)であって、該展開可能な組織アンカーは、それ自体の長手方向軸に沿って前進することによって展開し、発泡体の前記本体部(15)の側壁をこえて貫通して延在するように構成され、前記ハブ(111)に接続されている支持セグメント(122)と、制約された構成形状から展開された構成形状に展開するように構成されている組織係合セグメント(121)と、を備え、該展開可能な組織アンカーの前記組織係合セグメント(121)の先端が、前記本体部(15)を貫通して前記本体部(15)の外側へ組織内に延在して、前記本体部(15)を前記左心耳内にしっかり留める、少なくとも1つの展開可能な組織アンカー(1302、1405、1506、1601、1604)をさらに備え、
発泡体の前記本体部(15)内の材料が、前記ハブ(111)と前記支持セグメント(122)とを収容するために取り除かれていることを特徴とする、左心耳閉塞デバイス(10、204)。 - 複数の組織係合セグメント(121)が、複数の支持セグメントによって前記ハブと回転可能に結合され、複数の前記組織係合セグメント(121)が、回転して展開された構成形状になるように構成されている、複数の展開可能なアンカー(1302、1405、1506、1601、1604)をさらに備えていることを特徴とする、請求項1に記載の左心耳閉塞デバイス(10、204)。
- 複数の前記支持セグメントは、複数のストラットを備えていることを特徴とする、請求項2に記載の左心耳閉塞デバイス(10、204)。
- 発泡体の前記本体部(15)の取り除かれた前記材料は、複数の前記アンカー(1302、1405、1506、1601、1604)に対応する複数の軸方向に延在するスロットを画成し、複数の前記アンカーの各々は、対応する軸方向の前記スロットを通して展開し引っ込むように構成されていることを特徴とする、請求項2に記載の左心耳閉塞デバイス(10、204)。
- 前記アンカー(1302、1405、1506、1601、1604)を制約された構成形状に抑制する抑制具をさらに備え、前記アンカーは、前記抑制具を前記アンカーから取り外すことによって制約された構成形状から展開された構成形状に展開されることを特徴とする、請求項1に記載の左心耳閉塞デバイス(10、204)。
- 発泡体の前記本体部(15)の一部が、前記ハブ(111)および前記アンカー(1302、1405、1506、1601、1604)の遠位側に配置されていることを特徴とする、請求項1に記載の左心耳閉塞デバイス(10、204)。
- 発泡体の前記本体部(15)が、スキンをさらに備えていることを特徴とする、請求項1に記載の左心耳閉塞デバイス(10、204)。
- 前記本体部(15)の側壁に少なくとも1つの組織成長侵入面をさらに備えていることを特徴とする、請求項1に記載の左心耳閉塞デバイス(10、204)。
- 左心耳閉鎖システムであって、
近位端と、遠位端と、それらの中を貫通する少なくとも1つの内腔とを有する、細長可撓性チューブ状本体部を備えた送達カテーテルと、
請求項1に記載の左心耳閉塞デバイス(10、204)と、
を備えていることを特徴とする、左心耳閉鎖システム。 - 発泡体の前記本体部の取り除かれた前記材料は、複数のアンカー(1302、1405、1506、1601、1604)に対応する複数の軸方向に延在するスロットを画成し、複数の前記アンカーの各々は、対応する軸方向の前記スロットを通して展開し引っ込むように構成されていることを特徴とする、請求項9に記載の左心耳閉鎖システム。
- 前記アンカー(1302、1405、1506、1601、1604)を覆うことによって前記アンカーを制約された前記構成形状に抑制するシースをさらに備え、前記アンカーは、前記アンカーを覆うことから前記シースを外すことによって制約された構成形状から展開された構成形状に展開されることを特徴とする、請求項9に記載の左心耳閉鎖システム。
- 発泡体の前記本体部は、スキンをさらに備えていることを特徴とする、請求項9に記載の左心耳閉鎖システム。
- 前記スキンは、延伸ポリテトラフルオロエチレン(ePTFE)を含み、前記本体部の前記近位端を覆っていることを特徴とする、請求項12に記載の左心耳閉鎖システム。
- 発泡体の前記本体部は、円筒形であることを特徴とする、請求項1に記載の左心耳閉塞デバイス(10、204)。
- 前記スキンは、延伸ポリテトラフルオロエチレン(ePTFE)を含み、前記本体部の前記近位端を覆っていることを特徴とする、請求項7に記載の左心耳閉塞デバイス(10、204)。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562240124P | 2015-10-12 | 2015-10-12 | |
US62/240,124 | 2015-10-12 | ||
PCT/US2016/056450 WO2017066197A1 (en) | 2015-10-12 | 2016-10-11 | Devices and methods for excluding the left atrial appendage |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018531772A JP2018531772A (ja) | 2018-11-01 |
JP6899832B2 true JP6899832B2 (ja) | 2021-07-07 |
Family
ID=57206423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018538538A Active JP6899832B2 (ja) | 2015-10-12 | 2016-10-11 | 左心耳を排除するためのデバイスおよび方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3361961A1 (ja) |
JP (1) | JP6899832B2 (ja) |
WO (1) | WO2017066197A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6423851B2 (ja) | 2013-03-13 | 2018-11-14 | アーロン・ヴィ・カプラン | 左心耳に空置術を行うためのデバイス |
EP3531926A2 (en) | 2016-10-27 | 2019-09-04 | Conformal Medical, Inc. | Devices and methods for excluding the left atrial appendage |
EP3709899A4 (en) * | 2017-11-17 | 2021-12-08 | Surecor, Inc. | SYSTEM AND PROCEDURE FOR CLOSURE OF THE LEFT HEART |
EP3787525A4 (en) * | 2018-05-02 | 2022-06-22 | Conformal Medical, Inc. | DEVICES AND METHODS FOR LEFT ATRIAL APPENDAGE EXCLUSION |
US11241239B2 (en) | 2018-05-15 | 2022-02-08 | Boston Scientific Scimed, Inc. | Occlusive medical device with charged polymer coating |
US11589873B2 (en) | 2018-12-31 | 2023-02-28 | Biosense Webster (Israel) Ltd. | Occlusion detection by pressure measurement |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010148246A2 (en) * | 2009-06-17 | 2010-12-23 | Coherex Medical, Inc. | Medical device for modification of left atrial appendage and related systems and methods |
JP6423851B2 (ja) * | 2013-03-13 | 2018-11-14 | アーロン・ヴィ・カプラン | 左心耳に空置術を行うためのデバイス |
US11911258B2 (en) * | 2013-06-26 | 2024-02-27 | W. L. Gore & Associates, Inc. | Space filling devices |
-
2016
- 2016-10-11 WO PCT/US2016/056450 patent/WO2017066197A1/en active Application Filing
- 2016-10-11 EP EP16787663.0A patent/EP3361961A1/en active Pending
- 2016-10-11 JP JP2018538538A patent/JP6899832B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2018531772A (ja) | 2018-11-01 |
WO2017066197A1 (en) | 2017-04-20 |
EP3361961A1 (en) | 2018-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10617425B2 (en) | Devices and methods for excluding the left atrial appendage | |
US20240074766A1 (en) | Devices and methods for excluding the left atrial appendage | |
JP7071350B2 (ja) | 左心耳を排除するためのデバイスおよび方法 | |
JP6899832B2 (ja) | 左心耳を排除するためのデバイスおよび方法 | |
US20230071677A1 (en) | Devices and methods for excluding the left atrial appendage | |
US20190269413A1 (en) | Apparatus and method of monofilament implant delivery in a body vessel of a patient | |
EP1720456B1 (en) | Devices for closing a patent foramen ovale | |
JP2022519720A (ja) | 左心耳を排除するためのデバイスおよび方法 | |
JP7366933B2 (ja) | 左心耳を排除するためのデバイスおよび方法 | |
US20240197332A1 (en) | Devices and methods for excluding the left atrial appendage | |
WO2014102767A2 (en) | Apparatus and method of monofilament implant delivery in a body vessel of a patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180612 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191002 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200928 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201012 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210112 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210517 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210615 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6899832 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |